# OnCo record diamond (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/diamond/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "diamond", "NCT06954480" ;
  schema:name "DIAMOND"@en ;
  schema:description "DIAMOND, a UK trial run from Barts in London, asks whether adding the immunotherapy durvalumab to the antibody-drug conjugate datopotamab deruxtecan helps women with PD-L1-negative metastatic triple-negative breast cancer, the group immunotherapy alone does not help. It opened in October 2025 and is recruiting 140 patients."@en ;
  schema:url <https://onco.cc/trials/diamond/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06954480>, <https://www.isrctn.com/search?q=datopotamab+deruxtecan+durvalumab> ;
  onco:status "recruiting" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-metastatic/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/trop2/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/drugs/durvalumab/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:terms <https://onco.cc/terms/cps/> ;
  onco:trials <https://onco.cc/trials/tropion-breast02/>, <https://onco.cc/trials/nct03742102/>, <https://onco.cc/trials/tropion-breast05/> .